Results 1 to 10 of about 2,934 (166)
PLoS ONE, 2023 Lansoprazole, a proton pump inhibitor, can exert antioxidant effects through the induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, independently of the inhibition of acid secretion in the gastrointestinal tract.
Naoko Yamagishi +4 more
doaj +3 more sources
The effectiveness and cost of lansoprazole and pantoprazole for stress ulcer prophylaxis in intensive care unit [PDF]
Pharmaciana, 2021 The incidence of bleeding is increased in high risk patients with critical conditions in Intensive Care Unit (ICU). Appropriate prophylaxis medicine is necessary to reduce the incidence of stress ulcer bleeding during hospitalization in ICU which further
Mega Octavia +2 more
doaj +1 more source
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. [PDF]
PLoS ONE, 2014 Benzimidazole drugs lansoprazole and omeprazole are used for treatment of various gastrointestinal pathologies. Both compounds cause drug-drug interactions because they activate aryl hydrocarbon receptor and induce CYP1A genes.
Aneta Novotna, Zdenek Dvorak
doaj +1 more source
Efficacy of soluble lansoprazole-impregnated beta-tricalcium phosphate for bone regeneration
Scientific Reports, 2022 The proton pump inhibitor lansoprazole has been previously identified to upregulate the expression and transcriptional activity of runt-related transcription factor 2 (Runx2) that promotes lineage commitment and differentiation of osteoprogenitor cells ...
Kenichi Mishima +5 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2023 Background Proton pump inhibitors (PPIs) are common and widely used for gastrointestinal-related disorders. Lansoprazole is one of PPIs with potential benefits of anti-inflammation, reduced oxidative stress, and anti-diabetes.
Ming-Hsun Lin +5 more
doaj +1 more source
Lansoprazole-induced hypomagnesaemia [PDF]
BMJ Case Reports, 2014 The introduction of proton pump inhibitors (PPIs) in the late 1980s optimised the medical treatment of acid-related disorders. They are potent medications and have a good safety profile. However, long-term therapy with PPIs may carry undesired side effects, one of which is hypomagnesaemia. This entity is likely to be under-reported.
Lukasz Zbigniew Krupa, Ian W Fellows
openaire +3 more sources
Biosensors, 2023 The efficacies and toxicities of chiral drug enantiomers are often dissimilar, necessitating chiral recognition methods. Herein, a polylysine–phenylalanine complex framework was used to prepare molecularly imprinted polymers (MIPs) as sensors with ...
Lianming Zhang +5 more
doaj +1 more source
BMC Gastroenterology, 2023 Background VISION is a randomised, phase 4, open-label, parallel-group, multicentre study conducted in 33 centres in Japan. The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis ...
Ken Haruma +9 more
doaj +1 more source
Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines. [PDF]
PLoS ONE, 2014 Proton pump inhibitors omeprazole and lansoprazole contain chiral sulfur atom and they are administered as a racemate, i.e. equimolar mixture of S- and R-enantiomers.
Aneta Novotna +5 more
doaj +1 more source
Brazilian Journal of Pharmaceutical Sciences, 2015 The aim of this study was to evaluate the effects of caffeine, tea polyphenol and daidzein on the pharmacokinetics of lansoprazole and its metabolites. Rats were intragastrically administered caffeine (30 mg·kg-1, once per day), tea polyphenol (400 mg·kg-
Tao Wu +5 more
doaj +1 more source